Premium
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia
Author(s) -
Wierda William G.,
Byrd John C.,
O'Brien Susan,
Coutre Steven,
Barr Paul M.,
Furman Richard R.,
Kipps Thomas J.,
Burger Jan A.,
Stevens Don A.,
Sharman Jeff,
Ghia Paolo,
Flinn Ian W.,
Zhou Cathy,
Ninomoto Joi,
James Danelle F.,
Tam Constantine S.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15791
Subject(s) - ibrutinib , venetoclax , tumor lysis syndrome , medicine , oncology , chronic lymphocytic leukemia , adverse effect , progression free survival , rituximab , lymphoma , chemotherapy , leukemia